Q2 EPS Estimates for Avalo Therapeutics Raised by Wedbush

Avalo Therapeutics, Inc. (NASDAQ:AVTX - Free Report) - Analysts at Wedbush lifted their Q2 2025 earnings estimates for shares of Avalo Therapeutics in a research note issued on Thursday, March 20th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings per share of ($1.25) for the quarter, up from their prior forecast of ($1.40). Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for Avalo Therapeutics' current full-year earnings is ($19.07) per share. Wedbush also issued estimates for Avalo Therapeutics' Q3 2025 earnings at ($1.31) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($0.94) EPS, Q1 2026 earnings at ($0.79) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($0.66) EPS and FY2026 earnings at ($1.40) EPS.

Several other equities research analysts have also commented on the company. Jefferies Financial Group started coverage on Avalo Therapeutics in a research note on Tuesday. They set a "buy" rating and a $23.00 price target on the stock. Stifel Nicolaus began coverage on Avalo Therapeutics in a research report on Tuesday. They set a "buy" rating and a $36.00 target price on the stock. Piper Sandler initiated coverage on Avalo Therapeutics in a research report on Friday, February 28th. They issued an "overweight" rating and a $48.00 price target for the company. HC Wainwright reiterated a "neutral" rating on shares of Avalo Therapeutics in a research report on Thursday, March 20th. Finally, BTIG Research initiated coverage on shares of Avalo Therapeutics in a report on Thursday, December 19th. They set a "buy" rating and a $40.00 target price for the company. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $33.00.

Remove Ads

Avalo Therapeutics Trading Up 4.4 %

AVTX traded up $0.37 on Monday, hitting $8.73. 83,023 shares of the company were exchanged, compared to its average volume of 211,121. Avalo Therapeutics has a fifty-two week low of $4.60 and a fifty-two week high of $34.46. The business's fifty day moving average is $7.55 and its 200 day moving average is $9.13.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AVTX. Tower Research Capital LLC TRC lifted its holdings in Avalo Therapeutics by 998.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,130 shares of the company's stock valued at $31,000 after purchasing an additional 3,754 shares in the last quarter. Marshall Wace LLP acquired a new position in shares of Avalo Therapeutics in the fourth quarter valued at approximately $114,000. Walleye Capital LLC purchased a new position in shares of Avalo Therapeutics during the fourth quarter valued at approximately $145,000. Northern Trust Corp acquired a new stake in Avalo Therapeutics during the fourth quarter worth approximately $168,000. Finally, Bank of Montreal Can purchased a new stake in Avalo Therapeutics in the 4th quarter worth approximately $446,000. Hedge funds and other institutional investors own 87.06% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.